Mohammed Yousuf Karim

Author

Also Known As

M Karim, M Y Karim, M Yousuf Karim, M. Y. Karim, M. Yousuf Karim, M.Y. Karim, MY Karim, Md. Mozahedul Karim, Mohammed Karim, Mohammed Y. Karim

115

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

St Thomas' Hospital Guy's and St Thomas' NHS Foundation Trust Hamad bin Khalifa University Ludwig-Maximilians-Universität München University College London

About

Mohammed Yousuf Karim is an author at St Thomas' Hospital specializing in medicine, autoimmune disease, and autoimmunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	332
2	Immunology	3	3	144
3	Allergy	2	2	24
4	Health Sciences	1	1	11
5	Clinical Nutrition	1	1	13

Mohammed Yousuf Karim

Publications

982

Citations

H-Index

Page 1

	Year	Citations
Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents Mohammed Yousuf Karim British journal of rheumatology	2002	151
Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations Tiziana Lorenzini, Manfred Fliegauf, Nils Klammer, Journal of Allergy and Clinical Immunology Autoimmune DiseaseGenetic DisorderMedicineGeneticsImmunologic Phenotype	2020	120
Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus Mohammed Yousuf Karim, L. Cunha-Miranda, Colin Tench, Seminars in Arthritis and Rheumatism Lung SyndromeClinical FindingAutoimmune DiseaseSystemic Lupus ErythematosusLupus	2002	110
Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. Cecilia Pisoni, Francisco J. Sánchez-Gómez, Mohammed Yousuf Karim, PubMed	2005	103
Thalidomide for the treatment of resistant cutaneous lupus: Efficacy and safety of different therapeutic regimens María José Cuadrado, Mohammed Yousuf Karim, Giovanni Sanna, The American Journal of Medicine RheumatologyLupusMedicineLupus NephritisDifferent Therapeutic Regimens	2005	78
Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome Paula Alba, Mohammed Yousuf Karim, Beverley J. Hunt Lupus	2003	70
Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases Sonali Wijetilleka, David Jayne, Chetan Mukhtyar, Lara D. Veeken	2018	54
Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy Mohammed Yousuf Karim, C N Pisoni, Laura Ferro, Lara D. Veeken	2005	44
Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre. Inês Câmara, Savino Sciascia, Joana Simões, PubMed	2014	42
Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus and lupus nephritis Zoe Adhya, Mohammad El Anbari, Siddiq Anwar, Lupus	2019	33

Page 1